AI Article Synopsis

  • This report presents a case study on the use of dupilumab for treating eosinophilic fasciitis (EF), marking it as the first known instance of this treatment for the condition.
  • The findings suggest a connection between Type 2 innate immunity and eosinophilic fasciitis.
  • Additionally, it indicates that T helper 2 cytokines may play significant roles in the development and management of EF.

Article Abstract

This is the first report, to our knowledge, of the use of dupilumab in treating eosinophilic fasciitis (EF). Our case supports that Type 2 innate immunity might be related to EF and that T helper 2 cytokines play important roles in EF.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.15379DOI Listing

Publication Analysis

Top Keywords

eosinophilic fasciitis
8
dupilumab treatment
4
treatment eosinophilic
4
fasciitis report
4
report knowledge
4
knowledge dupilumab
4
dupilumab treating
4
treating eosinophilic
4
fasciitis case
4
case supports
4

Similar Publications

Eosinophilic fasciitis (EF) poses a diagnostic challenge owing to its uncommon occurrence and aetiology that remains poorly understood. We report a case of a 79-year-old woman with a prolonged history of breast cancer exhibiting EF with concomitant pelvic metastases. This case underscores EF's potential as an indicator signaling a potential resurgence of cancer, highlighting its significance as a red flag of disease recurrence.

View Article and Find Full Text PDF

A 61 year old male presented with clinical signs of Eosinophilic fasciitis (EF), a rare connective tissue disease. Early recognition of the diagnosis of EF is essential. Common examination findings are prayer sign and distal limb swelling, induration, venous guttering, and peau d'orange.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!